| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Kabi Pharmacia Oncology, S-223 63 Lund, Sweden [B. D., A. B., B. H-A.], and Department of Pharmacology, University of Texas Medical School, Houston, Texas 77225 [F. C.]
2 To whom requests for reprints should be addressed, at Department of Cell Biology, Kabi Pharmacia Oncology, Scheelevagen 22, S-223 63 Lund, Sweden.
To investigate the mechanism of action of the antineoplastic drug estramustine, we compared its effects on human prostate cancer cells with those of vinblastine. At their respective concentrations that result in 50% inhibition of clonogenic growth, both drugs caused an accumulation of cells blocked at mitosis and similar dose- and time-dependent depolymerization of interphase microtubules. Also, colcemid-resistant and colcemid-hypersensitive Chinese hamster ovary cells with tubulin mutations were collaterally cross-resistant or -sensitive to estramustine. Thus, the cytotoxicity of estramustine is due to its microtubule depolymerization properties. This could be caused by interaction with tubulin and/or with microtubule-associated proteins (MAPs). Previous investigations have shown that high concentrations of estramustine phosphate can inhibit microtubule polymerization in vitro by binding to MAPs. However, estramustine phosphate is the clinical prodrug to estramustine, the intracellular active compound. In this study, we investigated the effects of estramustine on the binding of MAPs to taxol-stabilized microtubulesin vivo. In contrast to previous reports, no effect of estramustine on the binding of MAPs to microtubules was found. Furthermore, we found that polymerization of purified tubulin could be inhibited by estramustine in vitro. Taken together, these results demonstrate that estramustine causes depolymerization of microtubules by direct interaction with tubulin.
1 This work was funded in part by Grant CA52962 from the National Institutes of Health to F. C.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 3/ 8/93. Accepted 7/19/93.
This article has been cited by other articles:
|
|
 |
|
  K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oudard, E. Banu, P. Beuzeboc, E. Voog, L. M. Dourthe, A. C. Hardy-Bessard, C. Linassier, F. Scotte, A. Banu, Y. Coscas, et al. Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer J. Clin. Oncol., May 20, 2005; 23(15): 3343 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, X. Hong, M. Hussain, S. H. Sarkar, R. Li, and F. H. Sarkar Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 389 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mobley, J. O. L'Esperance, M. Wu, C. J. Friel, R. H. Hanson, and S.-M. Ho The novel estrogen 17{alpha}-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17{beta}-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro Mol. Cancer Ther., May 1, 2004; 3(5): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hari, Y. Wang, S. Veeraraghavan, and F. Cabral Mutations in {alpha}- and {beta}-Tubulin That Stabilize Microtubules and Confer Resistance to Colcemid and Vinblastine Mol. Cancer Ther., July 1, 2002; 2(7): 597 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hudes, N. Haas, G. Yeslow, T. Gillon, P. O. Gunnarsson, M. Ellman, O. Nordle, B. Eriksson, L. Miller, L. Cisar, et al. Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate J. Clin. Oncol., February 15, 2002; 20(4): 1115 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Dixon, K. B. Knopf, and W. D. Figg The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verdier-Pinard, Z. Wang, A. K. Mohanakrishnan, M. Cushman, and E. Hamel A Steroid Derivative with Paclitaxel-Like Effects on Tubulin Polymerization Mol. Pharmacol., March 1, 2000; 57(3): 568 - 575. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Auclerc, E. C. Antoine, F. Cajfinger, A. Brunet-Pommeyrol, C. Agazia, and D. Khayat Management of Advanced Prostate Cancer Oncologist, February 1, 2000; 5(1): 36 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
G. Hudes, L. Einhorn, E. Ross, A. Balsham, P. Loehrer, H. Ramsey, J. Sprandio, M. Entmacher, W. Dugan, R. Ansari, et al. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial J. Clin. Oncol., October 1, 1999; 17(10): 3160 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Petrylak, R. B. Macarthur, J. O'Connor, G. Shelton, T. Judge, J. Balog, C. Pfaff, E. Bagiella, D. Heitjan, R. Fine, et al. Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer J. Clin. Oncol., March 1, 1999; 17(3): 958 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Panda, H. P. Miller, K. Islam, and L. Wilson Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action PNAS, September 30, 1997; 94(20): 10560 - 10564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Smith and X. Zhang Mechanism of Action of Cryptophycin J. Biol. Chem., March 15, 1996; 271(11): 6192 - 6198. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
